BRPI0607753A2 - método para prever um efeito clìnico em resposta a um tratamento de uma leucemia; método para prever um efeito clìnico de uma leucemia; método para selecionar um tratamento para um paciente com leucemia; método para o diagnóstico ou monitoramento de ocorrência, desenvolvimento, progressão ou tratamento de uma leucemia; arranjo para uso num método para prever um efeito clìnico para um paciente aml; arranjo para uso num método de diagnóstico de aml; meio legìvel por computador; kit para o prognóstico de aml - Google Patents

método para prever um efeito clìnico em resposta a um tratamento de uma leucemia; método para prever um efeito clìnico de uma leucemia; método para selecionar um tratamento para um paciente com leucemia; método para o diagnóstico ou monitoramento de ocorrência, desenvolvimento, progressão ou tratamento de uma leucemia; arranjo para uso num método para prever um efeito clìnico para um paciente aml; arranjo para uso num método de diagnóstico de aml; meio legìvel por computador; kit para o prognóstico de aml

Info

Publication number
BRPI0607753A2
BRPI0607753A2 BRPI0607753-6A BRPI0607753A BRPI0607753A2 BR PI0607753 A2 BRPI0607753 A2 BR PI0607753A2 BR PI0607753 A BRPI0607753 A BR PI0607753A BR PI0607753 A2 BRPI0607753 A2 BR PI0607753A2
Authority
BR
Brazil
Prior art keywords
leukemia
treatment
aml
predicting
clinical effect
Prior art date
Application number
BRPI0607753-6A
Other languages
English (en)
Inventor
Michael E Burczynski
Frederick Immermann
Jennifer Ann Stover
Andrew J Dorner
Natalie C Twine
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BRPI0607753A2 publication Critical patent/BRPI0607753A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

MéTODO PARA PREVER UM EFEITO CLìNICO EM RESPOSTA A UM TRATAMENTO DE UMA LEUCEMIA; MéTODO PARA PREVER UM EFEITO CLìNICO DE UMA LEUCEMIA; MéTODO PARA SELECIONAR UM TRATAMENTO PARA UM PACIENTE COM LEUCEMIA; MéTODO PARA O DIAGNóSTICO OU MONITORAMENTO DE OCORRêNCIA, DESENVOLVIMENTO, PROGRESSãO OU TRATAMENTO DE UMA LEUCEMIA; ARRANJO PARA USO NUM MéTODO PARA PREVER UM EFEITO CLìNICO PARA UM PACIENTE AML; ARRANJO PARA USO NUM MéTODO DE DIAGNóSTICO DE AML; MEIO LEGìVEL POR COMPUTADOR; KIT PARA O PROGNóSTICO DE AML. A presente invenção fornece métodos, sistemas e equipamento para o prognóstico, diagnóstico e seleção de tratamento de AML ou outros tipos de leucemia. Genes prognósticos de efeito clínico de pacientes com leucemia podem ser identificados de acordo com a presente invenção. Genes de doença de leucemia também podem ser identificados de acordo com a presente invenção. Esses genes são diferencialmente expressos em PBMCs de pacientes com AML em relação a seres humanos sem doença. Esses genes podem ser usados para o diagnóstico ou o monitoramento do desenvolvimento, progressão ou tratamento de AML.
BRPI0607753-6A 2005-02-16 2006-02-16 método para prever um efeito clìnico em resposta a um tratamento de uma leucemia; método para prever um efeito clìnico de uma leucemia; método para selecionar um tratamento para um paciente com leucemia; método para o diagnóstico ou monitoramento de ocorrência, desenvolvimento, progressão ou tratamento de uma leucemia; arranjo para uso num método para prever um efeito clìnico para um paciente aml; arranjo para uso num método de diagnóstico de aml; meio legìvel por computador; kit para o prognóstico de aml BRPI0607753A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65311705P 2005-02-16 2005-02-16
PCT/US2006/005855 WO2006089233A2 (en) 2005-02-16 2006-02-16 Methods and systems for diagnosis, prognosis and selection of treatment of leukemia

Publications (1)

Publication Number Publication Date
BRPI0607753A2 true BRPI0607753A2 (pt) 2009-10-06

Family

ID=36659874

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0607753-6A BRPI0607753A2 (pt) 2005-02-16 2006-02-16 método para prever um efeito clìnico em resposta a um tratamento de uma leucemia; método para prever um efeito clìnico de uma leucemia; método para selecionar um tratamento para um paciente com leucemia; método para o diagnóstico ou monitoramento de ocorrência, desenvolvimento, progressão ou tratamento de uma leucemia; arranjo para uso num método para prever um efeito clìnico para um paciente aml; arranjo para uso num método de diagnóstico de aml; meio legìvel por computador; kit para o prognóstico de aml

Country Status (14)

Country Link
US (1) US20080280774A1 (pt)
EP (1) EP1848994A2 (pt)
JP (1) JP2008529557A (pt)
KR (1) KR20070106027A (pt)
CN (1) CN101156067A (pt)
AU (1) AU2006214034A1 (pt)
BR (1) BRPI0607753A2 (pt)
CA (1) CA2598025A1 (pt)
CR (1) CR9315A (pt)
IL (1) IL185189A0 (pt)
MX (1) MX2007009911A (pt)
NO (1) NO20074104L (pt)
RU (1) RU2007130722A (pt)
WO (1) WO2006089233A2 (pt)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006125195A2 (en) * 2005-05-18 2006-11-23 Wyeth Leukemia disease genes and uses thereof
US10460080B2 (en) 2005-09-08 2019-10-29 Gearbox, Llc Accessing predictive data
KR100617467B1 (ko) * 2005-09-27 2006-09-01 디지탈 지노믹스(주) 급성 골수성 백혈병 환자의 항암제 치료 반응성 예측용마커
US20090075266A1 (en) * 2007-09-14 2009-03-19 Predictive Biosciences Corporation Multiple analyte diagnostic readout
CA2706881A1 (en) 2007-11-30 2009-06-11 Brian Z. Ring Tle3 as a marker for chemotherapy
WO2009120905A2 (en) 2008-03-26 2009-10-01 Cellerant Therapeutics, Inc. Immunoglobulin and/or toll-like receptor proteins associated with myelogenous haematological proliferative disorders and uses thereof
EP2113257A1 (en) 2008-04-30 2009-11-04 Consorzio per il Centro di Biomedica Moleculare Scrl Polyelectrolyte with positive net charge for use as medicament and diagnostic for cancer
US20100041055A1 (en) * 2008-08-12 2010-02-18 Stokes Bio Limited Novel gene normalization methods
US9365901B2 (en) 2008-11-07 2016-06-14 Adaptive Biotechnologies Corp. Monitoring immunoglobulin heavy chain evolution in B-cell acute lymphoblastic leukemia
US9528160B2 (en) 2008-11-07 2016-12-27 Adaptive Biotechnolgies Corp. Rare clonotypes and uses thereof
US8628927B2 (en) 2008-11-07 2014-01-14 Sequenta, Inc. Monitoring health and disease status using clonotype profiles
EP2364368B1 (en) * 2008-11-07 2014-01-15 Sequenta, Inc. Methods of monitoring conditions by sequence analysis
US8691510B2 (en) * 2008-11-07 2014-04-08 Sequenta, Inc. Sequence analysis of complex amplicons
US9506119B2 (en) 2008-11-07 2016-11-29 Adaptive Biotechnologies Corp. Method of sequence determination using sequence tags
US8748103B2 (en) 2008-11-07 2014-06-10 Sequenta, Inc. Monitoring health and disease status using clonotype profiles
ES2726702T3 (es) 2009-01-15 2019-10-08 Adaptive Biotechnologies Corp Perfilado de la inmunidad adaptativa y métodos para la generación de anticuerpos monoclonales
KR100937720B1 (ko) * 2009-04-20 2010-01-20 전남대학교산학협력단 ＣＦＨ 또는 ＡｐｏＨ를 급성골수성백혈병 관해 진단용 생화학적 마커로 사용하는 방법
WO2010151416A1 (en) 2009-06-25 2010-12-29 Fred Hutchinson Cancer Research Center Method of measuring adaptive immunity
RU2535635C2 (ru) * 2009-07-07 2014-12-20 Конинклейке Филипс Электроникс Н.В. Динамическое формирование изображений посредством позитронно-эмиссионной томографии с компенсацией загрязнений изотопами
GB2472856B (en) 2009-08-21 2012-07-11 Cantargia Ab IL1-RAP modulators and uses thereof
JP5503942B2 (ja) * 2009-10-30 2014-05-28 シスメックス株式会社 疾患の罹患の判定方法
US9043160B1 (en) 2009-11-09 2015-05-26 Sequenta, Inc. Method of determining clonotypes and clonotype profiles
JP5467267B2 (ja) * 2010-03-05 2014-04-09 国立大学法人大阪大学 機器制御装置、機器システム、機器制御方法、機器制御プログラム、および記録媒体
US9403906B2 (en) 2011-01-19 2016-08-02 Cantargia Ab Method of treatment of a solid tumor with interleukin-1 accessory protein antibody
US9012422B2 (en) * 2011-08-10 2015-04-21 Wake Forest University Health Sciences Method of treating acute myelogenous leukemia
US9873918B2 (en) 2011-08-11 2018-01-23 Albert Einstein College Of Medicine, Inc. Treatment of acute myeloid leukemia and myelodysplastic syndromes
US10385475B2 (en) 2011-09-12 2019-08-20 Adaptive Biotechnologies Corp. Random array sequencing of low-complexity libraries
EP2768982A4 (en) 2011-10-21 2015-06-03 Adaptive Biotechnologies Corp QUANTIFICATION OF ADAPTIVE IMMUNOCELL GENOMES IN A COMPLEX MIX OF CELLS
US9824179B2 (en) 2011-12-09 2017-11-21 Adaptive Biotechnologies Corp. Diagnosis of lymphoid malignancies and minimal residual disease detection
US9499865B2 (en) 2011-12-13 2016-11-22 Adaptive Biotechnologies Corp. Detection and measurement of tissue-infiltrating lymphocytes
JP6156621B2 (ja) * 2012-02-14 2017-07-05 国立大学法人 岡山大学 Ａｔｌｌの診断のためのデータ取得方法、ａｔｌｌ診断用キットおよびａｔｌｌ診断システム
EP3372694A1 (en) 2012-03-05 2018-09-12 Adaptive Biotechnologies Corporation Determining paired immune receptor chains from frequency matched subunits
HUE029357T2 (en) 2012-05-08 2017-02-28 Adaptive Biotechnologies Corp Preparations and devices for measuring and calibrating amplification distortion in multiplex PCR reactions
PL2857037T3 (pl) * 2012-05-31 2019-12-31 Kinki University Środek do leczenia profilaktycznego i/lub terapeutycznego obwodowego bólu neuropatycznego wywoływanego przez środek przeciwnowotworowy
EP3330384B1 (en) 2012-10-01 2019-09-25 Adaptive Biotechnologies Corporation Immunocompetence assessment by adaptive immune receptor diversity and clonality characterization
WO2015160439A2 (en) 2014-04-17 2015-10-22 Adaptive Biotechnologies Corporation Quantification of adaptive immune cell genomes in a complex mixture of cells
US9708657B2 (en) 2013-07-01 2017-07-18 Adaptive Biotechnologies Corp. Method for generating clonotype profiles using sequence tags
WO2015134787A2 (en) 2014-03-05 2015-09-11 Adaptive Biotechnologies Corporation Methods using randomer-containing synthetic molecules
US10066265B2 (en) 2014-04-01 2018-09-04 Adaptive Biotechnologies Corp. Determining antigen-specific t-cells
CA2966201A1 (en) 2014-10-29 2016-05-06 Adaptive Biotechnologies Corp. Highly-multiplexed simultaneous detection of nucleic acids encoding paired adaptive immune receptor heterodimers from many samples
US10246701B2 (en) 2014-11-14 2019-04-02 Adaptive Biotechnologies Corp. Multiplexed digital quantitation of rearranged lymphoid receptors in a complex mixture
AU2015353581A1 (en) 2014-11-25 2017-06-15 Adaptive Biotechnologies Corporation Characterization of adaptive immune response to vaccination or infection using immune repertoire sequencing
CA2976580A1 (en) 2015-02-24 2016-09-01 Adaptive Biotechnologies Corp. Methods for diagnosing infectious disease and determining hla status using immune repertoire sequencing
EP3277294B1 (en) 2015-04-01 2024-05-15 Adaptive Biotechnologies Corp. Method of identifying human compatible t cell receptors specific for an antigenic target
US11474106B2 (en) 2015-07-08 2022-10-18 Lawrence Livermore National Security, Llc Methods for cytotoxic chemotherapy-based predictive assays
US11035850B2 (en) 2016-04-12 2021-06-15 The Johns Hopkins University Quantitative determination of nucleoside analogue drugs in genomic DNA or RNA
US10428325B1 (en) 2016-09-21 2019-10-01 Adaptive Biotechnologies Corporation Identification of antigen-specific B cell receptors
WO2018132766A1 (en) * 2017-01-12 2018-07-19 The Regents Of The University Of California Cytotoxic chemotherapy-based predictive assays for acute myeloid leukemia
CN106841624B (zh) * 2017-01-26 2019-02-22 庄磊靓 抗人cd4和抗人cd184单克隆抗体作为标志物的应用
US11254980B1 (en) 2017-11-29 2022-02-22 Adaptive Biotechnologies Corporation Methods of profiling targeted polynucleotides while mitigating sequencing depth requirements
CN108182347B (zh) * 2018-01-17 2022-02-22 广东工业大学 一种大规模跨平台基因表达数据分类方法
KR102327062B1 (ko) 2018-03-20 2021-11-17 딜로이트컨설팅유한회사 임상시험 결과 예측 장치 및 방법
CN109187987B (zh) * 2018-08-23 2021-05-11 中国人民解放军第三0九医院 Ms4a3蛋白作为标志物在诊断活动性结核病中的应用
WO2020067389A1 (ja) 2018-09-28 2020-04-02 旭化成ファーマ株式会社 抗悪性腫瘍剤による末梢神経障害の症状軽減及び／又は発症抑制のための医薬
CN109897900B (zh) * 2019-03-13 2023-04-07 温州医科大学 Epb42基因在肝癌sbrt疗效评估中的应用
CN112831560B (zh) * 2019-11-23 2022-07-22 山东大学齐鲁医院 γ-分泌酶激活蛋白基因和/或其编码的蛋白的新应用
CN112852964B (zh) * 2021-03-08 2022-02-11 镇江市第一人民医院 一种环状RNA hsa_circ_0059707及其特异性扩增引物和应用
CN116200482B (zh) * 2021-11-30 2025-11-14 中山大学孙逸仙纪念医院 肌萎缩侧索硬化症分子诊断标志物及其应用
CN114712381B (zh) * 2022-03-30 2024-04-26 浙江大学 Ak2基因在制备白血病诱导分化治疗药物中的应用
CN115029383B (zh) * 2022-04-21 2024-02-20 苏天生命科技(苏州)有限公司 Ms4a3蛋白在调控红细胞成熟中的应用
CN115896280A (zh) * 2022-05-10 2023-04-04 广西医科大学第一附属医院 一种人肝癌酪氨酸激酶抑制剂耐药标志物及其应用
CN115165838B (zh) * 2022-06-23 2025-09-30 中国医学科学院血液病医院(中国医学科学院血液学研究所) 基于拉曼光谱和血清代谢构建mds和aml鉴别模型的方法和试剂盒
WO2024173551A2 (en) * 2023-02-17 2024-08-22 Calviri, Inc. Tryptophan neoantigen peptides for diagnostics, therapeutics, and vaccines
CN117737251B (zh) * 2024-02-21 2024-05-28 北京医院 一种aml诊断和预后的组合分子标志物
CN118465265A (zh) * 2024-04-08 2024-08-09 北京大学人民医院 与急性髓系白血病造血干细胞移植术后临床结局相关的生物标志物及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7625697B2 (en) * 1994-06-17 2009-12-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for constructing subarrays and subarrays made thereby
US6647341B1 (en) * 1999-04-09 2003-11-11 Whitehead Institute For Biomedical Research Methods for classifying samples and ascertaining previously unknown classes
US20010044103A1 (en) * 1999-12-03 2001-11-22 Steeg Evan W. Methods for the diagnosis and prognosis of acute leukemias
US20040018513A1 (en) * 2002-03-22 2004-01-29 Downing James R Classification and prognosis prediction of acute lymphoblastic leukemia by gene expression profiling
WO2003102235A2 (en) * 2002-05-31 2003-12-11 Cancer Research Technology Limited Specific genetic markets for cytogenetically defined acute myeloid leukaemia
US20040152632A1 (en) * 2002-11-06 2004-08-05 Wyeth Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome
EP1723257B1 (en) * 2004-02-23 2019-01-09 Erasmus University Medical Center Rotterdam Classification, diagnosis and prognosis of acute myeloid leukemia by gene expression profiling
AU2005201935B2 (en) * 2004-05-06 2012-04-26 Veridex, Llc Prognostic for hematological malignancy

Also Published As

Publication number Publication date
WO2006089233A2 (en) 2006-08-24
AU2006214034A1 (en) 2006-08-24
MX2007009911A (es) 2008-02-20
CN101156067A (zh) 2008-04-02
IL185189A0 (en) 2007-12-03
KR20070106027A (ko) 2007-10-31
EP1848994A2 (en) 2007-10-31
NO20074104L (no) 2007-11-13
RU2007130722A (ru) 2009-03-27
CA2598025A1 (en) 2006-08-24
CR9315A (es) 2008-01-21
US20080280774A1 (en) 2008-11-13
JP2008529557A (ja) 2008-08-07
WO2006089233A3 (en) 2007-03-29

Similar Documents

Publication Publication Date Title
BRPI0607753A2 (pt) método para prever um efeito clìnico em resposta a um tratamento de uma leucemia; método para prever um efeito clìnico de uma leucemia; método para selecionar um tratamento para um paciente com leucemia; método para o diagnóstico ou monitoramento de ocorrência, desenvolvimento, progressão ou tratamento de uma leucemia; arranjo para uso num método para prever um efeito clìnico para um paciente aml; arranjo para uso num método de diagnóstico de aml; meio legìvel por computador; kit para o prognóstico de aml
Zhai et al. Colon cancer recurrence‑associated genes revealed by WGCNA co‑expression network analysis
Rossor et al. Clinical implications of genetic advances in Charcot–Marie–Tooth disease
MX2013006669A (es) Conjunto de sondas de oligonucleotido y metodos para perfilado de microbiotica.
Song et al. The performance of the mSEPT9 assay is influenced by algorithm, cancer stage and age, but not sex and cancer location
WO2007011412A3 (en) Diagnosis and prognosis of infectious diesease clinical phenotypes and other physiologic states using host gene expresion biomarkers in blood
EP1810026A4 (en) B7-H1 AND METHOD FOR THE DIAGNOSIS, FORECAST AND TREATMENT OF CANCER
WO2021228067A8 (zh) 一种外周体液多标生物标志物检测中枢神经系统疾病的方法和系统
GB2478441A (en) Lung cancer biomarkers and uses thereof
WO2006084196A3 (en) Method for defining virtual patient populations
EP2566983A4 (en) SERIAL ANALYSIS OF BIOMARKERS FOR DISEASE DIAGNOSIS
WO2008013910A3 (en) Methods for identifying, diagnosing, and predicting survival of lymphomas
WO2009149026A3 (en) Genomic approaches to fetal treatment and diagnosis
HK1205764A1 (en) Tuberculosis biomarkers and uses thereof
BR112018015698A2 (pt) ?métodos diagnósticos e prognósticos para doenças cardiovasculares e eventos?
WO2010051314A3 (en) Genomic classification of non-small cell lung carcinoma based on patterns of gene copy number alterations
WO2002086448A3 (en) Detection of microsatellite instability and its use in diagnosis of tumors
WO2008128043A3 (en) Diagnostic and prognostic methods for renal cell carcinoma
WO2009040782A3 (en) A method of assessing colorectal cancer status in an individual
ATE375517T1 (de) Diagnosestellung von akuten myokardialen, ischämischen erkrankungen durch kombination von markern
Reinhart et al. Procalcitonin-a new marker of severe infection and sepsis
WO2007109733A3 (en) Diagnostic and prognostic markers and treatment strategies for multiple sclerosis
WO2008051992A3 (en) Systems and methods for analyzing and assessing attention deficit hyperactivity disorder
Ocheretina et al. Whole genome sequencing investigation of a tuberculosis outbreak in Port-au-Prince, Haiti caused by a strain with a “low-level” rpoB mutation L511P–insights into a mechanism of resistance escalation
WO2008103815A3 (en) Clinical intervention directed diagnostic methods

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DA 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2206 DE 16/04/2013.